Pfizer Inc (PFE)
Payables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 16,420,000 | 29,687,000 | 34,344,000 | 30,821,000 | 8,692,000 |
Payables | US$ in thousands | — | — | — | — | — |
Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $16,420,000K ÷ $—K
= —
Based on the data provided, Pfizer Inc's payables turnover ratio is not available for the years 2020, 2021, 2022, 2023, and 2024. The payables turnover ratio is a measure of how efficiently a company is managing its payments to suppliers. Without specific figures for payables turnover, it is difficult to assess Pfizer's ability to effectively manage its accounts payable and its relationships with vendors. Further details or historical data would be necessary to provide a more in-depth analysis of Pfizer's payables turnover performance over time.
Peer comparison
Dec 31, 2024
Company name
Symbol
Payables turnover
Pfizer Inc
PFE
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
19.54
Amphastar P
AMPH
11.74
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
8.33
Biomarin Pharmaceutical Inc
BMRN
—
Bristol-Myers Squibb Company
BMY
8.82
Catalyst Pharmaceuticals Inc
CPRX
—